» Articles » PMID: 25386087

Performance of the Montreal Classification for Inflammatory Bowel Diseases

Overview
Specialty Gastroenterology
Date 2014 Nov 12
PMID 25386087
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To validate the Montreal classification system for Crohn's disease (CD) and ulcerative colitis (UC) within the Netherlands.

Methods: A selection of 20 de-identified medical records with an appropriate representation of the inflammatory bowel disease (IBD) sub phenotypes were scored by 30 observers with different professions (gastroenterologist specialist in IBD, gastroenterologist in training and IBD-nurses) and experience level with IBD patient care. Patients were classified according to the Montreal classification. In addition, participants were asked to score extra-intestinal manifestations (EIM) and disease severity in CD based on their clinical judgment. The inter-observer agreement was calculated by percentages of correct answers (answers identical to the "expert evaluation") and Fleiss-kappa (κ). Kappa cut-offs: < 0.4-poor; 0.41-0.6-moderate; 0.61-0.8-good; > 0.8 excellent.

Results: The inter-observer agreement was excellent for diagnosis (κ = 0.96), perianal disease (κ = 0.92) and disease location in CD (κ = 0.82) and good for age of onset (κ = 0.67), upper gastrointestinal disease (κ = 0.62), disease behaviour in CD (κ = 0.79) and disease extent in UC (κ = 0.65). Disease severity in UC was scored poor (κ = 0.23). The additional items resulted in a good inter-observer agreement for EIM (κ = 0.68) and a moderate agreement for disease severity in CD (κ = 0.44). Percentages of correct answers over all Montreal items give a good reflection of the inter-observer agreement (> 80%), except for disease severity (48%-74%). IBD-nurses were significantly worse in scoring upper gastrointestinal disease in CD compared to gastroenterologists (P = 0.008) and gastroenterologists in training (P = 0.040). Observers with less than 10 years of experience were significantly better at scoring UC severity than observers with 10-20 years (P = 0.003) and more than 20 years (P = 0.003) of experience with IBD patient care. Observers with 10-20 years of experience with IBD patient care were significantly better at scoring upper gastrointestinal disease in CD than observers with less than 10 years (P = 0.007) and more than 20 years (P = 0.007) of experience with IBD patient care.

Conclusion: We found a good to excellent inter-observer agreement for all Montreal items except for disease severity in UC (poor).

Citing Articles

Functional characterization of novel anti-DEFA5 monoclonal antibody clones 1A8 and 4F5 in inflammatory bowel disease colitis tissues.

Thangaiyan R, Sakwe A, Hawkins A, Washington M, Ballard B, Izban M Inflamm Res. 2025; 74(1):30.

PMID: 39883179 PMC: 11782311. DOI: 10.1007/s00011-024-01970-w.


Endoscopic dilation of small-intestine strictures in Crohn's disease by balloon-assisted enteroscopy: a systematic review and meta-analysis.

Moond V, Gill V, Malik S, Kasture A, Parajuli S, Soni S Ann Gastroenterol. 2024; 37(6):682-694.

PMID: 39568704 PMC: 11574157. DOI: 10.20524/aog.2024.0920.


Anti-DEFA5 Monoclonal Antibody Clones 1A8 and 4F5 Immunoreactive Bioassay for Diagnosing Inflammatory Bowel Disease.

Thangaiyan R, Sakwe A, Hawkins A, Washington M, Ballard B, Izban M Res Sq. 2024; .

PMID: 39257990 PMC: 11384025. DOI: 10.21203/rs.3.rs-4843765/v1.


Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease.

Vernero M, Bezzio C, Ribaldone D, Costa S, Scalvini D, Tribocco E J Clin Med. 2023; 12(21).

PMID: 37959304 PMC: 10647534. DOI: 10.3390/jcm12216839.


Lifestyle Can Exert a Significant Impact on the Development of Metabolic Complications and Quality Life in Patients with Inflammatory Bowel Disease.

Garcia-Mateo S, Martinez-Dominguez S, Gargallo-Puyuelo C, Villarino M, Laredo De La Torre V, Gallego B Nutrients. 2023; 15(18).

PMID: 37764769 PMC: 10537893. DOI: 10.3390/nu15183983.


References
1.
Gasche C, Scholmerich J, Brynskov J, DHaens G, Hanauer S, Irvine E . A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000; 6(1):8-15. DOI: 10.1097/00054725-200002000-00002. View

2.
Festen E, Weersma R . How will insights from genetics translate to clinical practice in inflammatory bowel disease?. Best Pract Res Clin Gastroenterol. 2014; 28(3):387-97. DOI: 10.1016/j.bpg.2014.04.002. View

3.
Sands B . From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004; 126(6):1518-32. DOI: 10.1053/j.gastro.2004.02.072. View

4.
Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

5.
Price A . Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'. J Clin Pathol. 1978; 31(6):567-77. PMC: 1145346. DOI: 10.1136/jcp.31.6.567. View